The startup develops epigenetic biomarkers that analyze DNA methylation patterns and histone modifications to enhance cancer treatment development. These biomarkers enable earlier detection and accurate diagnosis, facilitating personalized oncology approaches for healthcare providers.
Funding
$550K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatment development faces challenges in early detection, accurate diagnosis, and personalized approaches due to limitations in analyzing epigenetic modifications. Traditional methods struggle to effectively utilize DNA methylation patterns and histone modifications for enhanced oncology treatments.
Solution
The company develops epigenetic biomarkers that analyze DNA methylation patterns and histone modifications to improve cancer treatment development. These biomarkers facilitate earlier and more accurate cancer diagnoses, enabling healthcare providers to implement personalized oncology approaches. By leveraging epigenetic data, the platform aims to provide insights into disease mechanisms, identify potential drug targets, and stratify patients based on their likelihood of response to specific therapies. The technology seeks to transform cancer care by providing clinicians with advanced tools for precision medicine.
Target Audience
The primary customers are healthcare providers and pharmaceutical companies involved in cancer treatment and drug development.
Features
- Analysis of DNA methylation patterns
- Analysis of histone modifications
- Biomarker discovery for early cancer detection
- Diagnostic tools for accurate cancer diagnosis
- Personalized oncology approaches based on epigenetic profiles